XML 73 R63.htm IDEA: XBRL DOCUMENT v3.21.2
COMMITMENTS AND CONTINGENCIES (Details)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 30, 2020
agreement
plaintiff
Dec. 31, 2019
USD ($)
opposingParty
patent
Sep. 30, 2021
USD ($)
Sep. 30, 2021
USD ($)
plaintiff
lawsuit
Dec. 31, 2016
party
Loss Contingencies [Line Items]          
Litigation accrual reversed | $     $ 175    
Number of patents challenged, scenario one | patent   4      
Number of patents challenged, scenario two | patent   2      
Juno Therapeutics, Inc. and Sloan Kettering Cancer Center          
Loss Contingencies [Line Items]          
Damages awarded | $   $ 585      
Running royalty rate from October 2017   27.60%      
Enhancement rate on past damages 50.00%        
Running royalty rate on future sales 27.60%        
ViiV Healthcare Company | Pending Litigation          
Loss Contingencies [Line Items]          
Damages amount | $       $ 16,400  
Pre-Exposure Prophylaxis          
Loss Contingencies [Line Items]          
Number of material transfer agreements | agreement 4        
European Patent Claims 2024 Expiration          
Loss Contingencies [Line Items]          
Number of parties appealed   2      
European Patent Claims 2026 Expiration          
Loss Contingencies [Line Items]          
Number of parties appealed   3      
European Patent Claims 2032 Expiration          
Loss Contingencies [Line Items]          
Number of parties appealed   3      
European Patent Claims 2027 Expiration          
Loss Contingencies [Line Items]          
Number of parties appealed   2      
Number of parties filing opposition | party         3
Product Liability          
Loss Contingencies [Line Items]          
Number of class action lawsuits | lawsuit       1  
Number of plaintiffs involved | plaintiff       24,000  
Qui Tam          
Loss Contingencies [Line Items]          
Number of plaintiffs involved | plaintiff 2